<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104031">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01695161</url>
  </required_header>
  <id_info>
    <org_study_id>MZ-MPS-2012-01</org_study_id>
    <nct_id>NCT01695161</nct_id>
  </id_info>
  <brief_title>Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.</brief_title>
  <acronym>MPSORA</acronym>
  <official_title>Corneal-Compensated Intraocular Pressure, Corneal Hysteresis and Corneal Resistance Factor Measurements Performed With the Ocular Response Analyzer and Their Correlation to Conventional Goldmann Applanation Tonometry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to compare intraocular pressure (IOP) values assessed with
      Ocular Response Analyzer to the classical gold standard of IOP measurement, to Goldmann
      applanation tonometry by mucopolysacchyridosis-, Fabry-patients and healthy controls. We
      want to investigate biomechanical characteristics of the cornea and their influence on the
      IOP-measurements.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>agreement between ccIOP and GAT in MPS, Fabry and healthy controls</measure>
    <time_frame>Sep 2013 (anticipated)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of agreement between ccIOP and GAT in MPS, Fabry and healthy controls</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Mucopolysaccharidosis</condition>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>mucopolysaccharidosis</arm_group_label>
    <description>mucopolysaccharidosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fabry disease</arm_group_label>
    <description>Fabry disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>healthy controls</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        25 eyes of MPS patients 25 eyes of Fabry patients 25 eyes of healthy age matched controls
        (a difference of ± 5 years in the mean between both groups is accepted)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MPS I, II, IV, VI patients with at least grade 3 of corneal clouding (Couprie et al.)

          -  Fabry patients with cornea verticillata &gt; grade 1

          -  Age ≥ 12 years

          -  Patient is able to comply with the study procedure

          -  Patient has consented to be in the trial

          -  Ability to fixate a target

        Exclusion Criteria:

          -  History of corneal transplantation or refractive surgery

          -  Corneal pathologies other than MPS-associated corneal opacity

          -  Corneal, conjunctival or intraocular inflammation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Pitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University Medical Center, Johannes Gutenberg-</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, University Medical Center, Johannes Gutenberg-</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Wasielica-Poslednik, MD</last_name>
      <phone>00496131173367</phone>
      <email>joanna.wasielica-poslednik@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 28, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Susanne Pitz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Mucopolysaccharidosis</keyword>
  <keyword>Fabry disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
